Back to top

Analyst Blog

Zacks Equity Research

Phase III Data on Novartis' RLX030

NVS AZN MRK

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Switzerland-based pharmaceutical company, Novartis AG (NVS - Snapshot Report) recently announced phase III data on its pipeline candidate, RLX030 (serelaxin), from the six month, RELAX-AHF study.

The study showed that treatment with RLX030 reduced the rate of mortality in patients suffering from acute heart failure (AHF), which has a higher death rate compared to other cardiovascular diseases.

The phase III RELAX-AHF study had two primary objectives which used different scales for measuring the reduction in dyspnea. The study managed to achieve one of the primary objectives. The study also revealed that RLX030 was well tolerated in patients.

The randomized, double-blind study, RELAX-AHF was conducted in 1,161 patients in 11 countries. The study evaluated the safety and efficacy of the candidate, RLX030, in the AHF indication versus placebo.

RLX030 along with loop diuretics and other medicines was administered to patients for up to 48 hours following hospitalization.

Novartis intends to discuss the results from the study with regulatory authorities around the globe. Data from the study will also be presented at the American Heart Association congress in November 2012.

Already approved heart failure treatments include AstraZeneca’s (AZN - Analyst Report) Toprol XL and Merck & Co.’s (MRK - Analyst Report) Prinvil.

We remind investors that in August 2012, Novartis had reported positive phase II data on its pipeline candidate, LCZ696, from the PARAMOUNT study for the treatment of chronic heart failure.

The study showed significant reduction in a key indicator of morbidity and mortality in patients suffering from chronic heart failure with preserved ejection fraction (HF-PEF).

Our Recommendation

Currently, we have a Neutral recommendation on Novartis. Novartis carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%